Adlai Nortye director Ji Ping sells $163,274 in ANL stock

Adlai Nortye Group Ltd. (NASDAQ:ANL) Director Ji Ping recently sold a total of $163,274 worth of American Depository shares, according to a filing with the U.S. Securities and Exchange Commission. The transactions occurred over two days in late September 2026.

Mr. Ping disposed of 10,214 shares across three separate transactions. On September 29, 2026, he sold 214 shares at a price of $15.77 per share. The following day, September 30, 2026, he conducted two separate sales, disposing of 5,000 shares at $16.03 per share and another 5,000 shares at $15.95 per share. The timing of these sales is notable, as the stock has since declined to $10.58, representing a significant drop from the director’s sale prices. Despite this recent weakness, ANL shares have delivered exceptional returns over the past year, up 540%, though the stock has retreated 28.5% over the past six months. The prices for these sales ranged from $15.77 to $16.03 per share. Following these reported transactions, Mr. Ping beneficially owns 121,453 American Depository shares of Adlai Nortye Group Ltd. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value estimate. Investors seeking deeper insights can access comprehensive financial health scores and additional ProTips on the platform.

In other recent news, Adlai Nortye Ltd. has garnered attention from multiple analyst firms, highlighting its potential in the pharmaceutical sector. Jefferies initiated coverage on the company with a buy rating and set a price target of $31.00. The firm’s analysis emphasized Adlai Nortye’s AN9025 drug candidate, noting its potentially best-in-class pan-RAS profile and durable tumor response with weekly dosing. Similarly, Lucid Capital Markets also began coverage with a buy rating, assigning a higher price target of $49.00. Lucid Capital Markets pointed out AN9025’s differentiated preclinical profile in terms of potency, durability, and therapeutic window potential. The firm further noted that following the approval of daraxonrasib, AN9025 no longer needs to prove the clinical viability of pan-RAS biology. These recent developments indicate a strong focus on Adlai Nortye’s innovative drug pipeline.